|Event Time:||Tuesday May 7, 2019 1:00 pm to 3:00 pm|
|Topic(s):||General Neurology, MS and CNS Inflammatory Disease|
|Director(s):||Paul George MD, PhD, MSE, Antonio Omuro MD|
|Description:||Stem cells represent an exciting possibility for neural therapeutics and have shown promise in ongoing clinical trials. This session presents current clinical cases demonstrating the promise and challenges of stem cell use in neurology today. The cases are followed by an in-depth look at the mechanisms of action of stem cells across multiple neurologic specialties and a discussion of where the field is headed.|
|Completion Message:||Participants will have knowledge of common clinical challenges that arise with patients seeking stem cell therapies and receive an update of current breakthroughs in the field.|
|Core Competencies:||Patient Care, Medical Knowledge|
|1:00 PM - 1:05 PM||Introduction||Paul M. George MD, PhD, MSE|
|1:05 PM - 1:15 PM||Clinical Cases||Paul M. George MD, PhD, MSE|
|1:15 PM - 1:40 PM||The Basic Science of Stem Cells||Sean I. Savitz MD|
|1:40 PM - 1:50 PM||Current State of Stem Cells in Neurology||Paul M. George MD, PhD, MSE|
|1:50 PM - 2:00 PM||Perils of Stem Cell Tourism||Jaime Imitola MD, FAAN|
|2:30 PM - 3:00 PM||Panel Discussion||Paul M. George MD, PhD, MSE, Antonio M. P. Omuro MD|
|Paul M. George, MD, PhD, MSE||Dr. George has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with medical legal and GLG consulting.|
|Jaime Imitola, MD, FAAN||Biogen- consultant Associate editor- Journal of Neuroimmunology|
|Antonio M. P. Omuro, MD||Dr. Omuro has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BMS, Merck, Stemline, Novocure, AstraZeneca, Inovio, and Alexion Pharmaceuticals. Dr. Omuro has received research support from Merck.|
|Sean I. Savitz, MD||Dr. Savitz has nothing to disclose.|
|1:00 PM||001||Peripheral Nerve Grafting as a Disease Modifying Cell Therapy for Parkinson’s Disease||
Dr. El Seblani has nothing to disclose.
Phase I/II Clinical Trials Testing Multiple Dosing of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Patients with Progressive MS
Dr. Sadiq has nothing to disclose.
Ready to register for the 2019 AAN Annual Meeting?
|8:00 AM-9:30 AM|
Neuroimaging for the General Neurologist
Ryan Hakimi DO